Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 4Recurrence 2Brain Neoplasms 2Astrocytoma 2Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Lomustine × Clear all
NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated
403 enrolled
CNS

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡